EGF and nasopharyngeal carcinoma: Within the prior study three different metastatic states were recreated: i) growing (Hep/NPC plus MDA-MB-231; a mix of actively proliferating and non-proliferating cancer cells), dormant (Hep/NPC plus MDA-MB-231 then doxorubicin; non-proliferating cancer cells) and emergent (Hep/NPC plus MDA-MB-231, then doxorubicin followed by LPS/EGF; reawakened proliferating cancer cells).